-
2023-506918-45-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2023-506919-18-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2022-501252-28-00
4
2021-04-15
Non Small Cell Lung cancer
-
2024-511403-41-00
4
2021-04-14
Advanced or metastatic squamous cell carcinoma of the esophagus
-
2023-504990-19-00
5
2021-04-06
Agitation in Patients With Dementia of the Alzheimer's Type
-
2023-503291-24-00
9
2021-03-17
Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected
-
2023-503771-13-00
4
2021-01-28
Classic Congenital Adrenal Hyperplasia
-
2024-511067-29-00
5
2021-01-25
IgA Nephropathy
-
2023-503770-21-00
4
2021-01-05
Classic Congenital Adrenal Hyperplasia
-
2022-502031-20-00
10
2020-12-17
Non-squamous non-small cell lung cancer (NSCLC)
-
2023-504571-25-00
3
2020-10-20
Relapsed or Refractory Multiple Myeloma
-
2022-500820-31-00
4
2020-07-16
Recurrent or metastatic squamous cell carcinoma of the head and neck
-
2024-511171-15-00
3
2020-07-06
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
-
2023-507024-24-00
5
2020-05-05
Metastatic hormone sensitive prostate cancer
-
2024-512448-41-00
5
2020-04-01
Bronchiolitis Obliterans Syndrome in Patients post Single or post Doub
-
2023-503749-76-00
1
2020-03-06
Solid Tumors
-
2023-507904-30-00
3
2020-01-27
solid tumors
-
2023-508364-29-00
5
2019-11-22
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-507669-24-00
5
2019-11-05
Chronic lymphocytic leukemia
-
2024-512967-29-00
4
2019-09-03
Hypoparathyroidism (HP) in Adults
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2023-509304-16-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2024-516735-27-00
5
2019-01-31
Fabry disease (α-galactosidase A deficiency)
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.